19,800 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Acquired by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board acquired a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,800 shares of the biotechnology company's stock, valued at approximately $1,727,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth $62,028,000. Jennison Associates LLC purchased a new stake in Blueprint Medicines in the 4th quarter worth $31,417,000. Wellington Management Group LLP raised its holdings in Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after acquiring an additional 316,754 shares during the period. William Blair Investment Management LLC lifted its holdings in Blueprint Medicines by 16.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after purchasing an additional 269,896 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Blueprint Medicines in the fourth quarter worth $21,104,000.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares of the company's stock, valued at $6,581,655.32. This trade represents a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company's stock, valued at $1,692,167.40. The trade was a 14.92 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Stephens reaffirmed an "overweight" rating and set a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Needham & Company LLC lowered their price target on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday. JMP Securities reiterated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines presently has an average rating of "Moderate Buy" and an average target price of $124.53.

Blueprint Medicines Trading Down 0.0 %

NASDAQ BPMC traded down $0.03 on Tuesday, reaching $88.48. 93,187 shares of the company were exchanged, compared to its average volume of 767,443. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The stock has a market capitalization of $5.65 billion, a P/E ratio of -81.99 and a beta of 0.75. The business's fifty day moving average price is $87.46 and its 200 day moving average price is $93.18. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.